GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (FRA:JX7) » Definitions » Institutional Ownership

Embecta (FRA:JX7) Institutional Ownership : 71.74% (As of Jun. 07, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Embecta Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Embecta's institutional ownership is 71.74%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Embecta's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Embecta's Float Percentage Of Total Shares Outstanding is 71.35%.


Embecta Institutional Ownership Historical Data

The historical data trend for Embecta's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta Institutional Ownership Chart

Embecta Historical Data

The historical data trend for Embecta can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 89.15 78.82 75.95 75.66 71.23 71.37 71.71 72.15 71.86 71.74

Embecta Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Embecta (FRA:JX7) Business Description

Traded in Other Exchanges
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.

Embecta (FRA:JX7) Headlines

No Headlines